Dr. Jones serves as the Physician Lead for the Critical Limb Ischemia Program at New York Presbyterian Brooklyn Methodist Hospital. He also serves as the Chief Innovation Officer for Everbeat, a novel medical wearable start-up. Dr. Jones received his medical degree from Morehouse School of Medicine and completed his residency at New York Presbyterian Columbia University Medical Center. He received his Cardiology, and Interventional Cardiology fellowship training at the University of Pittsburgh Medical Center and Mount Sinai Medical Center, respectively.
His interests are cardiovascular medical device ideation and development.
Elazer R. Edelman is Edward Poitras Professor Medical Engineering and Science MIT, Professor of Medicine Harvard Medical School, and Senior Attending Physician Brigham and Women’s Hospital. He directs MIT’s Institute for Medical Engineering and Sciences dedicated to applying physical sciences to biologic processes and disease mechanisms, and home to graduate and medical doctoral degrees programs.
His research interests meld medical and scientific training leveraging pathophysiologic insight to improve clinical decision-making and device design. More than 350 students and fellows have passed through Edelman’s laboratory publishing over 900 scientific articles and 90 patents.
Edelman is fellow of American College of Cardiology, American Heart Association, Association of University Cardiologists, American Society of Clinical Investigation, American Institute of Medical and Biological Engineering, American Academy of Arts and Sciences, National Academy of Inventors, National Academy of Medicine, and National Academy of Engineering. As Chief Scientific Advisor of Science: Translational Medicine he has set the tone for the national debate on translational research and innovation. As co-founder of ASTM F04.03 he helped create standards for cardiovascular implants. He served on FDA’s Science Board and as ORISE fellow FDA EIR
Dr. Waxman serves as the Division Director of Cardiology in the Department of Medicine at Newark Beth Israel Medical Center. Dr. Waxman received his medical degree from the Universidad Anahuac in his native Mexico City. He then completed his residency in Internal Medicine as well as fellowships in Cardiology and Interventional Cardiology at the New England Deaconess Hospital, a teaching hospital of Harvard Medical School, in Boston, MA. He is Board Certified in Cardiovascular Medicine and Interventional Cardiology.
Dr. Osborn is an Interventional Cardiologist at Beth Israel Deaconess Medical Center in Boston, MA and faculty at Harvard Medical School. He received his M.D. from Harvard Medical School and PhD. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology. His clinical and research interests include intravascular imaging and coronary physiology.
Dr. Vucic earned his MD degree from the University of Tuebingen, Germany. He then completed a postdoctoral fellowship at the Department of Physiology at Yale University, New Haven. He then continued with his internship at SUNY Downstate, Brooklyn, New York and residency in internal medicine at Mount Sinai St. Luke’s-Mount Sinai West, New York. Following his training in Internal Medicine, Dr. Vucic performed research training in advanced cardiac imaging focused on Magnetic Resonance Imaging, Computed Tomography and Nuclear imaging at the Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York. He then completed fellowships in Cardiovascular Disease at Mount Sinai Hospital, New York, Advanced Cardiac Imaging at the Massachusetts General Hospital, Boston and Cardiac Electrophysiology at New York University, New York.
He joined Newark Beth Israel, in 2019 and is heading the advanced cardiac imaging service with a focus on cardiac MRI and cardiac CT.
DSc, MBA, FACHE
Dr. Tim Attebery serves as a consultant and strategic advisor to healthcare organizations including life-science and digital health companies, hospitals and health systems, medical groups, and other organizations. Before starting his own consulting firm, Dr. Attebery was the CEO of the American College of Cardiology and MedAxiom. Before taking the helm at the ACC, he served as the President/CEO of Holston Valley Medical Center in Kingsport, Tennessee, with oversight responsibilities for HVMC Main Campus, HVMC’s 10 outpatient locations, Hawkins County Memorial Hospital in Rogersville, and Hancock County Hospital in Sneedville. Prior to his HVMC role, Dr. Attebery was the System Vice-President of Cardiovascular Services for Wellmont Health System and CEO of Cardiovascular Associates.
He has 35 years of healthcare consulting and senior management experience including serving as the CEO of three large cardiovascular group practices. He served as the President of the Cardiology Advocacy Alliance for two years; CAA is a not-for-profit organization providing federal lobbying and advocacy for 7,000 cardiologists nationwide. He was instrumental in the initial founding of MedAxiom and the Society of Cardiovascular CT. He has authored/co-authored numerous published articles on hospital mergers, strategic planning, advanced cardiac imaging, emerging healthcare services, and healthcare IT.
He has a BS degree in Business Administration from Western Governors University; an MBA from the University of Tennessee Knoxville, Haslam College of Business; and a doctoral degree in healthcare leadership from the University of Alabama at Birmingham. He is a Fellow of, and board certified in healthcare administration by, the American College of Healthcare Executives.
Dr. Kevin J. Croce is an interventional cardiologist and the director of the Chronic Total Occlusion Complex Percutaneous Coronary Intervention Program at Brigham and Women’s Hospital (BWH). He is an assistant professor of medicine at Harvard Medical School (HMS) who also directs the BWH Translational Discovery Laboratory which is a centralized research facility that uses state-of-the-art technology to perform preclinical testing of promising therapies and medical devices.
Dr. Croce received his medical and Ph.D. degrees from Tufts University School of Medicine. He completed an internal medicine residency, a cardiology fellowship and an interventional cardiology fellowship at BWH. Dr. Croce is board certified in internal medicine, cardiovascular disease and interventional cardiology.
His clinical interests include advanced treatments for obstructive coronary artery disease (CAD), and optimization of antithrombotic and antiplatelet pharmacotherapy. The author of over 110 peer-reviewed publications, Dr. Croce’s research focuses on understanding the molecular pathobiology of atherothrombotic (CAD) and on identifying new targets for CAD treatment. His research has received support from the National Institutes of Health.
Dr. Eli V. Gelfand is Section Chief, General Cardiology at Beth Israel Deaconess Cardiovascular (BIDMC) and Harvard Medical School, where he directs an outpatient practice of over 30 clinicians, serving approximately 25,000 outpatient visits per year. He is also on staff at the BIDMC Echocardiography Lab and Cardiovascular Magnetic Resonance Center. Dr. Gelfand received his medical degree from the University of Illinois College of Medicine. He then completed a residency in Internal Medicine at Brigham and Women’s Hospital and a fellowship in Cardiovascular Diseases at Beth Israel Deaconess Medical Center, both teaching hospitals of Harvard Medical School in Boston, MA. He is Board Certified in Cardiovascular Diseases, Adult Echocardiography and Internal Medicine.
C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. The institutes have led over 1,000 studies, published 3,000 manuscripts in the peer review literature, and have led 60 FDA submissions from their network of 7,000 sites worldwide. In 2014 Gibson was ranked as one of the world’s most highly cited authors in all of science in the past decade by Thomson Reuters.
Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack.
For years, Gibson has been chosen as one of Boston’s Top Doctors & U.S. News & World Report also lists Gibson as one of America’s top doctors. Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count, the TIMI myocardial perfusion grade).
Dr. Gibson did his internship, residency and chief residency at the Brigham and Women’s Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School. Dr. Gibson has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology and as a Vice Chairman of Medicine.
Gibson founded WikiDoc.org and WikiPatient.org, widely viewed open source textbooks of medicine. He is Editor-In-Chief of >2,200 active contributors who have edited the content of over 100,000 chapters millions of times. Gibson also founded www.clinicaltrialresults.org and has conducted >2,200 TV / video interviews. Gibson has hundreds of thousands of followers on social media where he is a leading influencer.
BOSTON, Oct. 1, 2020 /PRNewswire/ — Dyad Medical, Inc., a groundbreaking medical image analysis platform delivering cloud-based artificial intelligence (AI)-based analysis, announced after just 90 days, the closing of its oversubscribed Series Seed funding round led by The Unofficial Syndicate, with participation by Social Starts L.P., and local angel investors. Along with grants from the NIH, this brings Dyad’s total funding to more than $3.5MM.
Dyad, a recent Mass Challenge grad, will use the funding to enhance its patent-pending cardiac imaging software, to accelerate its FDA clearance path and expand their team to prepare for customer deployments. Dyad’s cloud-native platform increases the accuracy and efficiency of cardiac image analysis providing cardiologist and clinicians with near real-time observations that, prior to Dyad, in many cases were invisible to the human eye and time consuming to detail.
“We are the only solution that provides cardiologists with insights on every scan they perform, regardless of the modality used and what part of the heart they scan,” says Dr. Ronny Shalev, co-founder and CEO of Dyad Medical. “We are clear on our goal to provide universal access to expert-level observations by teaching computers to automatically analyze medical images. The Dyad platform, will provide instantaneous cardiac image interpretations globally via the web, accessible by any device, which for a clinician is like having 1000’s of expert second opinions for them to consider in their diagnoses – all in real-time.”
“The combination of artificial intelligence, a brain trust of distinguished scientific advisors, and a cloud-based solution that delivers the only four modality cardiac analysis in the market is game changing. We believe this will become the gold standard in cardiac care and we are excited to help them bring this technology to market,” said Jayme Fishman, Co-founder of The Unofficial Syndicate. “My co-founder, Harry Scott, brought this deal to our consortium and will lead Dyad’s Advisory board as we help them move to commercialization.”
“We believe Dyad will transform the cardiac imaging field by placing cutting-edge technology within cardiologists’ current workflow to efficiently drive faster and more accurate diagnoses,” said Emi Gonzalez, Principal at Social Starts.
About Dyad Medical
Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to more efficiently interpret medical image content from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners “thousands of second opinions” in real-time. Within the digital diagnostics arena, Dyad Medical’s core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined.
About The Unofficial Syndicate
Irreverently named The Unofficial Syndicate is an active angel investment group of “non-members” known for high touch, thoughtful analysis and speed of decision making in finding and nurturing Seed stage companies navigate their formative years. www.TheUnofficialSyndicate.com
About Social Starts
Social Starts is a venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds. Focusing on companies that leverage social and mobile technologies with a particular emphasis on the emerging science and technology of health and happiness www.SocialStarts.com.
Boston, Massachusetts—Nov. 14, 2019—Dyad Medical, a leading provider of deep learning medical image analysis software, announced that it has joined the new Qualcomm® XR Enterprise Program (XEP). The new program allows enterprise solution providers to be part of a global community that offers access to technical support resources, promotional opportunities, co-marketing, joint planning and business development and matchmaking with other members for the collective goal of accelerating the enterprise XR segment to help increase operational efficiencies, worker satisfaction & safety and impact the bottom line.
Dyad Medical develops cardiac medical image interpretation software platform. Dyad Medical’s technology incorporates artificial intelligence to investigate image content and combines it with state-of-the-art visualization technologies to visualize analysis results, guide the clinicians and support diagnostic decision making.
“We’re thrilled to join the exceptional list of startups in the XR Enterprise program, which supports our vision of streamlining patient treatment, reducing diagnostic error rates and making image analysis more accessible,” said Ronny Shalev, PhD, cofounder and CEO of Dyad Medical. “Joining the program will help support our goal for expansion into new markets and help ensure our AI offering continues to be ahead of the curve.”
Dyad Medical is a pioneer in the development of deep learning architectures enabling quick and accurate medical image analysis and interpretation. With a platform developed by data scientists, machine learning practitioners, and medical experts, Dyad Medical is researching and developing analysis algorithms of heart images generated by a variety of data sources improving diagnostic accuracy.
Qualcomm invents breakthrough technologies that transform how the world computes, connects and communicates. When we connected the phone to the Internet, the mobile revolution was born. Today, our inventions are the foundation for life-changing products, experiences, and industries. As we lead the world to 5G, we envision this next big change in cellular technology spurring a new era of intelligent, connected devices and enabling new opportunities in connected cars, remote delivery of health care services, and the IoT — including smart cities, smart homes, and wearables. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, all of our engineering, research and development functions, and all of our products and services businesses, including, the QCT semiconductor business. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.
Qualcomm and Snapdragon are trademarks of Qualcomm Incorporated, registered in the United States and other countries.
Qualcomm Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries. The Qualcomm Advantage Network is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Find out more at www.dyadmed.com and follow us on Twitter and LinkedIn.
Contact about this news:
Dyad Medical, Inc.
Ronny Shalev, PhD
Boston, Massachusetts—June 14, 2019—Dyad Medical, a deep learning medical image analytics company, announced that it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data science.
Dyad Medical develops clinical applications using artificial intelligence, aimed at enabling doctors to more efficiently and effectively interpret medical image content. Dyad Medical’s solutions will be offered in two spaces:
Dyad Medical will also benefit from access to hardware grants, best-in-class training and more.
“We’re thrilled to join the exceptional list of startups in the NVIDIA Inception program, which supports our vision of streamlining medical image analysis and interpretation, reducing error rates and making image analysis more accessible,” said Ronny Shalev, cofounder and CEO of Dyad Medical. “Joining the program will help support our goal for expansion into new markets and help ensure our AI offering continues to be ahead of the curve.”
NVIDIA’s Inception program is a virtual accelerator program that helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, from hardware grants and marketing support to training with deep learning experts.
Dyad Medical is a pioneer in the development of deep learning architectures enabling quick and accurate medical image analysis and interpretation. With a platform developed by data scientists, machine learning practitioners, and medical experts, Dyad Medical is researching and developing analysis algorithms of images generated by a variety of data sources improving diagnostic accuracy. Dyad Medical was recently selected to participate in the 2019 MassChallenge Boston accelerator program representing the top 9% of applications from around the world, including 61 countries and 25 U.S. states. Find out more at www.dyadmed.com and follow us on Twitter and Linkedin.
Contact about this news:
Dyad Medical, Inc.
Ronny Shalev, PhD
Dyad Medical joins global network of startups
Boston, Massachusetts, May 15, 2019 – Dyad Medical, deep learning imaging analytics company, today announced that it was selected to participate in the 2019 MassChallenge Boston accelerator program. Rigorously selected by a community of close to 200 expert judges, Dyad Medical represents the top 9% of applications from around the world, including 61 countries and 25 U.S. states.
Through a global network of zero-equity accelerators, MassChallenge identifies the world’s highest-impact, highest-potential startups and helps them successfully launch and grow. As part of the 2019 cohort, Dyad Medical will have unrivaled access to expert mentorship, top corporate partners, and more than 20,000 square-feet of co-working space – all at zero cost and for zero equity. Dyad Medical will also engage in evidence-based curriculum, which has been designed to address key challenges throughout each phase of the early-stage lifecycle, including discovery, development, deployment, and distribution. At the close of the program, startups will compete for more than $1M in cash prizes at the 2019 MassChallenge Boston Awards held on October 24.
“We are on a mission to provide a cardiologist an insight with every single scan they perform, regardless of the modality used and what part of the heart they scan,” says Dr. Ronny Shalev, co-founder and CEO of Dyad Medical. “While we are clear on our goal to provide universal access to expert-level diagnosis by teaching computers to automatically analyze medical images, we are grateful that others understand where we’re going and believe in our mission. Our thanks to MassChallenge for supporting us!”
Dyad Medical develops clinical applications using artificial intelligence aimed at enabling doctors to more efficiently and effectively interpret medical image content. Within the digital diagnostics arena, Dyad Medical’s core focus is in Cardiovascular (more people die as a result of cardiovascular disease than all types of cancer combined) and Neuroradiology image analytics. Dyad Medical’s solutions will be offered in two spaces:
MassChallenge is a global network of zero-equity startup accelerators. Headquartered in the United States with locations in Boston, Israel, Mexico, Rhode Island, Switzerland, and Texas, MassChallenge is committed to strengthening the global innovation ecosystem by supporting high-potential startups across all industries, from anywhere in the world. To date, more than 1,900 MassChallenge alumni have raised more than $4 billion in funding, generated more than $2.5 billion in revenue, and created more than 120,000 total jobs.